420570.Kq
The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products and medical research, generating revenue primarily through the sale of its drug formulations and related healthcare services.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products and medical research, generating revenue primarily through the sale of its drug formulations and related healthcare services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products and medical research, generating revenue primarily through the sale of its drug formulations and related healthcare services.
The company maintains a strong capital structure, with a debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing and a robust equity base. Its liquidity position is characterized by a current ratio of 7.09, suggesting ample short-term assets to cover liabilities. However, the risk assessment notes a medium liquidity risk, with net cash being negative after subtracting total debt, which could signal potential short-term cash flow constraints.
Profitability metrics show a return on equity (ROE) of 7.91% and a return on assets (ROA) of 7.02%, both of which are strong indicators of efficient asset utilization and profitability. These figures are in line with the industry's preferred metrics, suggesting the company is performing at or above the median for its sector.
The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could pose a concentration risk, as the company's performance is tied to a single operational area.
Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. Historical revenue data and the absence of a forecasted change suggest a conservative outlook, with the company likely to continue its current operational pace.
Risk factors include a medium liquidity risk and a low dilution potential, with no significant dilution sources identified in the available data. The company's capital structure remains stable, with no recent events indicating a need for equity issuance or debt restructuring.
Recent events, including filings and transcripts, are not detailed in the available data, but the company's financial health and operational stability suggest a low likelihood of material adverse events in the near term. The absence of recent dilutive events supports the low dilution risk assessment.
- The company has a strong equity base and a low debt-to-equity ratio, indicating a conservative capital structure.
- Profitability metrics are robust, with ROE and ROA exceeding the industry median.
- The company's revenue is concentrated in a single segment, which could increase exposure to sector-specific risks.
- Liquidity risk is moderate, with a current ratio of 7.09 but a negative net cash position after debt.
- No significant dilution risk is present, and the company's capital structure remains stable.
- The company is expected to maintain a stable growth trajectory with no significant changes in revenue forecasted.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 420570.KQ Market data — financials · 2026-05-26